Trade Olema Pharmaceuticals, Inc. - OLMA CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.09 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 4.46 |
| Open | 4.33 |
| 1-Year Change | -69.64% |
| Day's Range | 4.33 - 4.6 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 7, 2025 | 4.56 | 0.10 | 2.24% | 4.46 | 4.62 | 4.32 |
| Mar 6, 2025 | 4.46 | 0.39 | 9.58% | 4.07 | 4.60 | 4.07 |
| Mar 5, 2025 | 4.23 | 0.04 | 0.95% | 4.19 | 4.30 | 4.09 |
| Mar 4, 2025 | 4.16 | 0.04 | 0.97% | 4.12 | 4.39 | 4.03 |
| Mar 3, 2025 | 4.19 | -0.14 | -3.23% | 4.33 | 4.53 | 4.14 |
| Feb 28, 2025 | 4.33 | 0.02 | 0.46% | 4.31 | 4.46 | 4.24 |
| Feb 27, 2025 | 4.36 | -0.16 | -3.54% | 4.52 | 4.63 | 4.25 |
| Feb 26, 2025 | 4.55 | -0.05 | -1.09% | 4.60 | 4.73 | 4.50 |
| Feb 25, 2025 | 4.61 | -0.16 | -3.35% | 4.77 | 4.86 | 4.49 |
| Feb 24, 2025 | 4.79 | -0.12 | -2.44% | 4.91 | 4.99 | 4.76 |
| Feb 21, 2025 | 4.94 | -0.14 | -2.76% | 5.08 | 5.15 | 4.90 |
| Feb 20, 2025 | 5.03 | -0.10 | -1.95% | 5.13 | 5.14 | 4.98 |
| Feb 19, 2025 | 5.11 | 0.13 | 2.61% | 4.98 | 5.22 | 4.87 |
| Feb 18, 2025 | 4.99 | 0.02 | 0.40% | 4.97 | 5.32 | 4.97 |
| Feb 14, 2025 | 4.93 | 0.17 | 3.57% | 4.76 | 5.10 | 4.76 |
| Feb 13, 2025 | 4.78 | -0.10 | -2.05% | 4.88 | 4.95 | 4.73 |
| Feb 12, 2025 | 4.90 | -0.12 | -2.39% | 5.02 | 5.08 | 4.80 |
| Feb 11, 2025 | 5.17 | 0.18 | 3.61% | 4.99 | 5.20 | 4.84 |
| Feb 10, 2025 | 5.13 | -0.53 | -9.36% | 5.66 | 5.66 | 4.75 |
| Feb 7, 2025 | 5.64 | -0.56 | -9.03% | 6.20 | 6.27 | 5.64 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Olema Pharmaceuticals, Inc. Company profile
About Olema Pharmaceuticals Inc
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. It was designed based on a structural understanding of the ER. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including a breast cancer brain metastasis model. It’s been ongoing Phase 1/2 clinical trial, and in Phase 1b combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Olema Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders increased from $24M to $71.1M. Higher net loss reflects Research and development increase from $11.7M to $41.8M (expense), Stock-based Compensation in R&D increase from $2M to $9.3M (expense), General and administrative - Balancing increase from $6.7M to $13.8M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
780 Brannan Street
SAN FRANCISCO
CALIFORNIA 94103
US
News
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com